"Dr. Mandel has been involved in studying T-cell vaccination using autologous T-cell lines generated from MS patients for the past six years," said Jim C. Williams, Ph.D., PharmaFrontiers' chief operating officer. "She will be a valued advisor on production of our vaccine when we begin our Phase IIb clinical trials of Tovaxin(TM) for the treatment of multiple sclerosis. This trial is expected to begin in the first quarter of 2006 and will eventually be held at approximately 30 sites, in the U.S., Canada, and Israel."
Dr. Mandel completed her M.D. at the Sackler School of Medicine in Tel-Aviv, Israel in 1981 and also holds a Masters in Health Management from Leon Recanaty Faculty of Management of Tel-Aviv University.
Dr. Williams added, "Dr. Mandel is joining an impressive clinical advisory board comprised of some of the thought leaders in the field of neurology and immunology."
Other members of the clinical advisory board are:
Douglas Arnold, M.D., James McGill Professor of Neurology and Neurosurgery at the Montreal Neurological Institute of McGill University; Scott R. Burger, M.D., Principal of Advanced Cell & Gene Therapy, LLC in Chapel Hill, North Carolina; Patricia K. Coyle, M.D., Professor of Neurology and Director of the Multiple Sclerosis Comprehensive Care Center at Stony Brook University Hospital in Stony Brook, New York; Edward J. Fox, M.D., Ph.D., Director of the Multiple Sclerosis Clinic of Central Texas in Round Rock, Lead Principal Investigator for the Tovaxin trials; George Hutton, M.D., Assistant Medical Director for the Maxine Mesinger MS Clinic of Baylor College of Medicine and The Methodist Hospital in Houston; Brian D. Loftus, M.D., Director of Neurology Research at the Diagnostic Clinic of Houston, Principal Investigator for Tovaxin trials; and, Jingwu Zhang, M.D., Ph.D., Professor of Neurology and Immunology at Baylor College of Medicine and Scientific Director of the Baylor-Methodist Multiple Sclerosis Center in Houston.
About PharmaFrontiers Corp
PharmaFrontiers is developing and commercializing cell therapies to treat several major disease areas led by Tovaxin to treat multiple sclerosis as well as cardiac and pancreatic conditions. PharmaFrontiers owns patented and proprietary individualized cell therapies that are employed in treating MS. The Company also holds the exclusive worldwide license from the University of Chicago, through its relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood. More information may be found on the Company's website at www.pharmafrontierscorp.net.
Safe Harbor Statement
This press release contains "forward-looking statements," including statements about PharmaFrontiers' growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to PharmaFrontiers' ability to obtain additional funding, develop its stem cell technologies, achieve its operational objectives, and obtain patent protection for its discoveries, that may cause PharmaFrontiers' actual results to be materially different from any future results expressed or implied by such forward-looking statements. PharmaFrontiers undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.